Publication: Indocyanine green fluorescence versus blue dye or radioisotope regarding detection rate of sentinel lymph node biopsy and nodes removed in breast cancer: A systematic review and meta-analysis
0
0
Issued Date
2020
Resource Type
File Type
application/pdf
ISSN
15137368
Other identifier(s)
2-s2.0-85085554781
Rights Holder(s)
Scopus
Bibliographic Citation
Asian Pacific Journal of Cancer Prevention. Vol 21, No.5 (2020), p.1187-1195
Suggested Citation
Thongvitokomarn S., Polchai N. Indocyanine green fluorescence versus blue dye or radioisotope regarding detection rate of sentinel lymph node biopsy and nodes removed in breast cancer: A systematic review and meta-analysis. Asian Pacific Journal of Cancer Prevention. Vol 21, No.5 (2020), p.1187-1195. doi:10.31557/APJCP.2020.21.5.1187 Retrieved from: https://hdl.handle.net/20.500.14740/4576
Author(s)
Abstract
Background: Either blue dye (BD) or radioisotope (RI) is mainly used for sentinel lymph node biopsy (SLNB) in breast cancer patients. Unlike the BD, RI has lower false-negative rate of SLNB. However, its lymphoscintigraphy, difficulty in preoperative injection, and undetected sentinel lymph nodes in some cases cause surgeons to rely only on BD. Currently, indocyanine green (ICG) fluorescence method (ICG-SLNB) is increasingly used as an alternative to the conventional mapping methods in many centers. This systematic review compared ICG with the conventional method of BD or RI in terms of detection rate of SLNB and the number of sentinel lymph nodes (SLNs) removed in. Methods: We searched all relevant studies published between January 2000 and October 2019. All data on for evaluation of SLN detection rate, number of SLNs removed per patient, and tumor positive rate of SLNB were extracted. Results: A total of 30 studies, including 4,216 SLN procedures were retrieved. There was a statistically significant difference between ICG and BD method in terms of SLN detection rate (OR, 6.73; 95% CI, 4.20-10.78). However, there was no significant difference between ICG and RI in this regard (OR, 0.90; 95% CI, 0.40-2.03). The number of SLNs removed per patient were 2.35 (1.46-5.4), 1.92 (1.0-3.64), and 1.72 (1.35-2.08) for ICG, BD, and RI, respectively. Only in 8 studies, the tumor positive rates in SLNB could be analyzed (ICG, 8.5-20.7%; BD, 12.7-21.4%; RI, 11.3-16%). Conclusion: ICG-SLNB could be an additional or an alternative method for axillary node mapping in breast cancer. © 2020, Asian Pacific Organization for Cancer Prevention.